Pharma Contract Development and Manufacturing Organizations (CDMOs) play a key role in the production of medicines globally, and the market is expected to continue growing between 2023 and 2030. As the industry grows, it continues to consolidate with the top few companies having majority of the market.

A&M’s EMEA Healthcare & Life Sciences and Ops & Supply Chain teams have shared their predictions for CDMOs in 2030, and their perspectives on what CDMOs should be addressing now to achieve success in the future.

The key predictions are that:

1. CDMO market will be worth $223.5 billion in 2030 with CDMOs following a range of growth strategies including expansions along the value chain and extension to different drug types
2. Three main types of CDMOs will exist in 2030 following further consolidation: scale players, focused businesses and specialised CDMOs
3. CDMO manufacturing footprints will change significantly in response to rising labour costs, geopolitical challenges and requirement for greater supply chain resilience
4. ESG considerations will become even more important for CDMOs; environmental performance will be a key criterion for CDMO selections; social responsibility will help win skilled talent, and governance and data integrity will be essential for success.

Download the report to find out more about these key predictions and priority actions for CDMOs in the future. If you would like to discuss this further, please contact Lee Feander.